What you believe and what you value as an organization matters. Discover the DNA of our firm.
Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.
Read about some of the latest events, partnerships, and business highlights from Sands Capital.
From aquaculture to semiconductors, European firms are quietly becoming global leaders in innovation, sustainability, and value creation.
In this episode of What Matters Most, Sands Capital Portfolio Manager and Sr. Research Analyst Danielle Menichella discusses the business’ journey from Taser maker to artificial intelligence-powered software developer.
Executive Managing Director and Senior Portfolio Manager Brian Christiansen discusses the importance of candor, collaboration, and entrepreneurialism in creating a culture that promotes long-term thinking.
FPT has harnessed education to drive Vietnam’s digital transformation and human-capital development.
Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.
Our latest annual report offers a comprehensive view of how we add value through active stewardship.
Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.
Sands Capital invests in innovative businesses across all stages of the growth spectrum
2016
Sands Capital (2021 – 2022)
Arlington, VA | Partner
Sands Capital (2018 – 2021)
Arlington, VA | Principal
Sands Capital (2018)
Arlington, VA | Sr. Associate
Sands Capital (2016 - 2017)
Arlington, VA | Venture Associate
T. Rowe Price (2016)
Baltimore, MD | Equity Research Extern
Johns Hopkins University (2008 - 2010)
Baltimore, MD | Laboratory Technician
Dickstein Shapiro LLP (2005 - 2007)
Washington, D.C. | Paralegal
Johns Hopkins University
PhD | School of Medicine
Washington & Lee University
BA | Philosophy
Stephen is a managing partner on the Life Sciences Pulse strategy, which he founded in 2019. Stephen joined Sands Capital in 2016. He has served on the boards of several therapeutics, diagnostics, and life sciences tools portfolio companies. Stephen received a PhD in neuroscience from the Johns Hopkins School of Medicine. He attended Columbia University for postbaccalaureate studies and received a BA in philosophy from Washington and Lee University. Stephen is a member of the Kauffman Fellows.
Notice for non-US Investors